Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?

8 Sept 2021

Abstract excerpt

Immunotherapy has transformed the treatment landscape of melanoma; however, despite improvements in patient outcomes, monotherapy can often lead to resistance and tumour escape. Therefore, there is a need for new therapies, combination strategies and biomarker-guided decision making to increase the subset of patients most likely to benefit from treatment. Poly (ADP-ribose) polymerase (PARP) inhibitors act by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34572747
DOI: 10.3390/cancers13184520

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?PMID 34572747Read ↗

PARP Inhibition as a Treatment Modality in Melanoma: What We Have Learned and What We Hope to AchieveSemantic proximity Read ↗

Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma TreatmentSemantic proximity Read ↗

PARP4 deficiency enhances sensitivity to ATM inhibitor by impairing DNA damage repair in melanomaSemantic proximity Read ↗

PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In VivoSemantic proximity Read ↗

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint InhibitorsSemantic proximity Read ↗

Homologous Recombination Deficiency (HRD) in Cutaneous OncologySemantic proximity Read ↗

The potential of PARP inhibitors in targeted cancer therapy and immunotherapySemantic proximity Read ↗

Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanomaSemantic proximity Read ↗

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid TumorsSemantic proximity Read ↗

Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency–Related Loss of HeterozygositySemantic proximity Read ↗

Update on Combination Strategies of PARP InhibitorsSemantic proximity Read ↗

Development of PARP and Immune-Checkpoint Inhibitor CombinationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.